Journal of Clinical Oncology, Vol 16, 683-691, Copyright © 1998 by American Society of Clinical Oncology

ARTICLES

Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group

S Stewart, H Jablonowski, FD Goebel, K Arasteh, M Spittle, A Rios, D Aboulafia, J Galleshaw and BJ Dezube
Department of Oncology, St Mary's Hospital, London, UK. simon@dukeau.demon.co.uk

PURPOSE: Cytotoxic chemotherapy is frequently required for the more severe manifestations of human immunodeficiency virus (HIV)-related Kaposi's sarcoma. Combinations of bleomycin and vincristine (BV) or BV with the addition of doxorubicin (ABV) are the most commonly used regimens against which new treatments may be compared. We report a multicenter phase III study that compared pegylated liposomal doxorubicin (PLD) to the BV combination. PATIENTS AND METHODS: We conducted a randomized study that compared PLD 20 mg/m2 with a combination of bleomycin 15 IU/m2 and vincristine 2 mg in 241 patients with HIV-related Kaposi's sarcoma. Both regimens were administered by intravenous infusion every 3 weeks for six cycles. RESULTS: A total of 121 patients received PLD and 120 patients the BV combination. The response to PLD was superior to BV: 58.7% versus 23.3% (P < .001). Patients who were randomized to receive BV, however, were more likely to terminate treatment early because of an adverse event (26.7% v 10.7%), and fewer completed the full six cycles of treatment (30.8% v 55.4%). Treatment with BV was associated with a significantly higher incidence of peripheral neuropathy (P < .001), whereas PLD treatment was more commonly associated with neutropenia and delays in receiving treatment (P < or = .001). CONCLUSION: Pegylated liposomal doxorubicin is an effective treatment for HIV-related Kaposi's sarcoma with a higher response rate than the BV combination. It is well tolerated but more myelosuppressive.

This article has been cited by other articles:

				J.-P. Spano, D. Costagliola, C. Katlama, N. Mounier, E. Oksenhendler, and D. Khayat AIDS-Related Malignancies: State of the Art and Therapeutic Challenges J. Clin. Oncol., October 10, 2008; 26(29): 4834 - 4842. [Abstract] [Full Text] [PDF]

				A. Lo, C.-T. Lin, and H.-C. Wu Hepatocellular carcinoma cell-specific peptide ligand for targeted drug delivery Mol. Cancer Ther., March 1, 2008; 7(3): 579 - 589. [Abstract] [Full Text] [PDF]

				M. Joshi, N. Markelova, D. Palacio, and R. M. Schapira A Patient With HIV, Dyspnea, and Multiple Pulmonary Nodules Chest, December 1, 2006; 130(6): 1924 - 1928. [Full Text] [PDF]

				Y. Fujisaka, A. Horiike, T. Shimizu, N. Yamamoto, Y. Yamada, and T. Tamura Phase 1 Clinical Study of Pegylated Liposomal Doxorubicin (JNS002) in Japanese Patients with Solid Tumors Jpn. J. Clin. Oncol., December 1, 2006; 36(12): 768 - 774. [Abstract] [Full Text] [PDF]

				M. C. Cheung, L. Pantanowitz, and B. J. Dezube AIDS-Related Malignancies: Emerging Challenges in the Era of Highly Active Antiretroviral Therapy Oncologist, June 1, 2005; 10(6): 412 - 426. [Abstract] [Full Text] [PDF]

				J. Stebbing, A. Wildfire, S. Portsmouth, T. Powles, C. Thirlwell, P. Hewitt, M. Nelson, S. Patterson, S. Mandalia, F. Gotch, et al. Paclitaxel for anthracycline-resistant AIDS-related Kaposi's sarcoma: clinical and angiogenic correlations Ann. Onc., November 1, 2003; 14(11): 1660 - 1666. [Abstract] [Full Text] [PDF]

				D. M. Aboulafia, D. Norris, D. Henry, R. J. Grossman, J. Thommes, D. Bundow, R. C. Yocum, and V. Stevens 9-cis-Retinoic Acid Capsules in the Treatment of AIDS-Related Kaposi Sarcoma: Results of a Phase 2 Multicenter Clinical Trial Arch Dermatol, February 1, 2003; 139(2): 178 - 186. [Abstract] [Full Text] [PDF]

				S. R. Evans, S. E. Krown, M. A. Testa, T. P. Cooley, and J. H. Von Roenn Phase II Evaluation of Low-Dose Oral Etoposide for the Treatment of Relapsed or Progressive AIDS-Related Kaposi's Sarcoma: An AIDS Clinical Trials Group Clinical Study J. Clin. Oncol., August 1, 2002; 20(15): 3236 - 3241. [Abstract] [Full Text] [PDF]

				O. Lyass, A. Hubert, and A. A. Gabizon Phase I Study of Doxil-Cisplatin Combination Chemotherapy in Patients with Advanced Malignancies Clin. Cancer Res., October 1, 2001; 7(10): 3040 - 3046. [Abstract] [Full Text] [PDF]

				H. J. Landau, B. J. Poiesz, S. Dube, J. A. Bogart, L. B. Weiner, and A.-K. Souid Classic Kaposi's Sarcoma Associated with Human Herpesvirus 8 Infection in a 13-Year-Old Male: A Case Report Clin. Cancer Res., August 1, 2001; 7(8): 2263 - 2268. [Abstract] [Full Text] [PDF]

				J. A. Sparano, U. Malik, L. Rajdev, C. Sarta, U. Hopkins, and A. C. Wolff Phase I Trial of Pegylated Liposomal Doxorubicin and Docetaxel in Advanced Breast Cancer J. Clin. Oncol., June 15, 2001; 19(12): 3117 - 3125. [Abstract] [Full Text] [PDF]

				K. J. Harrington, S. Mohammadtaghi, P. S. Uster, D. Glass, A. M. Peters, R. G. Vile, and J. S. W. Stewart Effective Targeting of Solid Tumors in Patients With Locally Advanced Cancers by Radiolabeled Pegylated Liposomes Clin. Cancer Res., February 1, 2001; 7(2): 243 - 254. [Abstract] [Full Text]

				K. J. Harrington, G. Rowlinson-Busza, K. N. Syrigos, P. S. Uster, R. G. Vile, and J. S. W. Stewart Pegylated Liposomes Have Potential as Vehicles for Intratumoral and Subcutaneous Drug Delivery Clin. Cancer Res., June 1, 2000; 6(6): 2528 - 2537. [Abstract] [Full Text]

				K. Antman and Y. Chang Kaposi's Sarcoma N. Engl. J. Med., April 6, 2000; 342(14): 1027 - 1038. [Full Text] [PDF]

				D. C. Drummond, O. Meyer, K. Hong, D. B. Kirpotin, and D. Papahadjopoulos Optimizing Liposomes for Delivery of Chemotherapeutic Agents to Solid Tumors Pharmacol. Rev., December 1, 1999; 51(4): 691 - 744. [Abstract] [Full Text] [PDF]

				P. S. Gill, A. Tulpule, B. M. Espina, S. Cabriales, J. Bresnahan, M. Ilaw, S. Louie, N. F. Gustafson, M. A. Brown, C. Orcutt, et al. Paclitaxel Is Safe and Effective in the Treatment of Advanced AIDS-Related Kaposi's Sarcoma J. Clin. Oncol., June 1, 1999; 17(6): 1876 - 1876. [Abstract] [Full Text] [PDF]